ICCPP ODM+ Will Bring the Unheard-of Double Eco-friendly Concept "Cyclo" Vape Solutions To The Vaper Expo UK 2023 Birmingham
9.5.2023 14:07:00 EEST | Business Wire | Press release
With the global prevalence of disposable e-cigarettes, there are growing concerns about the environmental problems caused. As one of key influencers of electronic atomization technology companies, as well as the parent company of VOOPOO, ICCPP Group takes these problems seriously and its ODM+ business has creatively developed world’s 1st new dual environmentally-friendly disposable vape solutions, named "Cyclo" series, which combines the concept of detachable and biodegradable, ahead of the industry in advance to achieve user portability and recyclability, will be grandly unveiled at the Vaper Expo UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005592/en/
The "Cyclo" eco-friendly vape solutions of ICCPP ODM+ (Photo: Business Wire)
Patented PLA Material: The Key to Make Stable Biodegradability Reality The "Cyclo" series are made with our exclusive and patented PLA material, a biodegradable material that is made from starch raw materials proposed from corn, a renewable plant resources, and which can be degraded into carbon dioxide and water in 3-6 months after being recycled and landfilled in the soil, making it a more environmentally friendly material.
In addition, ICCPP has gone through thousands of trials and tests and created a unique internal structure and process to further enhance the stability of unique PLA material, making it maintain its initial strength after thousands of drop and impact tests, to greatly improve the stability and safety of PLA e-cigarette sticks, without destroying the original biodegradable advantages of the material.
Leadless and Modular Design: Making Detachability A Reality
ICCPP’s commitment to environmental sustainability goes much further than just material selection.
We have implemented a wide range of environmentally-friendly design features, including no-soldering lead-free design and pre-automated modular assembly. These design features mean that "Cyclo" vape solutions can be easily disassembled for recycling or disposal, minimizing the environmental impact of manufacturing and using processes.
Multiple Options for Atomization Coils: The Addition of Environmental Concepts
ICCPP’s commitment to environmental sustainability does not end with the product itself. We have also advanced atomization coil technology into "Cyclo" series, resulting in a longer lifespan, less material waste, and a more stable and pure taste for vapers.
The atomization coil technology in the "Cyclo" vape solutions includes the mesh coil technology and the Gene Tree ceramic coil technology. On one hand, our mesh coil technology combines different resistivity application scenarios with a unique multi-layer distribution structure to precisely control the power at a single point and precisely calculate the heat field coverage at a single point to so that the heat is evenly distributed, resulting in a stable, perfect and pure taste.
On the other hand, the Gene Tree ceramic coil technology uses the exclusive powder-free environmental-friendly technology process, nano-microcrystalline ceramic material fired at 3000°, and a multi-layer A+ grade oil guide and oil lock aperture structure to provide more stable and uniform heating. This unique combination of technologies ensures that "Cyclo" e-cigarettes solutions provide customers with more puffs, purer tastes, greater flavor consistency and a superior vaping experience, as well as less environmental concerns .
The Origin of "Cyclo": The Commitment of ICCPP to the Environment and Society
In view of these, we name the electronic cigarettes solutions "Cyclo", representing our dedication to creating a closed-loop, circular product cycle that is both environmentally-friendly and sustainable. Also,the slogan of “Cyclo” is “Cycle of all things", and it reflects our dedications and determination to promoting environmental sustainability in all areas of our business.
In conclusion, the "Cyclo" series of e-cigarettes are the perfect choice for those who want an environmentally-friendly and sustainable vaping experience. With biodegradable materials, recyclable design features, cutting-edge atomization coil technology, as well as our commitment to environmental responsibility, we invite you to join us in the journey towards a more sustainable future.
Of course, apart from “Cyclo” eco-friendly products, ICCPP ODM+ brings dozens of vapes including refillable pods and disposable pods for UK e-cigarette enthusiasts and industry experts that meet local market flavor and puff preferences and also obey local regulations. Welcome to E10 booth at NEC of Birmingham and we look forward to seeing you on May 12th-14th 2023.
1) About ICCPP ODM+:
ICCPP ODM+ is an innovative ODM strategic cooperation model created by ICCPP Group in 2022, which puts forward the business proposition of “branding first, product integrating technology and marketing”.
Through all-round innovations and breakthroughs in technology+, product+, flavor+, quality+, compliance+ and marketing+, ICCPP ODM+ provides more premium vape solutions and services for customers' brands, so as to bring a healthier and happier electronic atomization life to global consumers and to achieve long-term development of both customers' brands and ICCPP ODM.
2) About ICCPP Group:
ICCPP Group, the parent company of VOOPOO, is a comprehensive electronic atomization ecological group with the whole industrial chain layout. It is rapidly developing with a new business model of matrix, internationalization and platform, integrating technology R&D, product design, intelligent manufacturing, brand operation and supply chain management.
With 9 years of full industry chain layout and global localization, ICCPP's electronic atomization products and solutions have been applied in more than 70 countries worldwide, covering 100,000 offline outlets and more than 36 million consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005592/en/
Contact information
Carol Lu
carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
